1. European Medicines Agency.First two CAR‐T cell medicines recommended for approval in the European Union. European Medicines Agency. Published September 17 2018.https://www.ema.europa.eu/en/news/first‐two‐car‐t‐cell‐medicines‐recommended‐approval‐european‐union. Accessed January 21 2021.
2. Chimeric antigen receptor T‐cell therapy toxicities
3. Alliance for Regenerative Medicine.Clinical Trials in Europe: Recent Trends in ATMP Development. Published2019.https://alliancerm.org/wp‐content/uploads/2019/10/Trends‐in‐Clinical‐Trials‐2019‐Final_Digital.pdf. Accessed January 21 2021.
4. European Commission. Horizon 2020.Horizon 2020 ‐ European Commission.2021.https://ec.europa.eu/programmes/horizon2020/en/h2020‐section/health‐demographic‐change‐and‐wellbeing. Accessed January 22 2021.
5. Innovative Medicines Initiative.Innovative Medicines Initiative. IMI Innovative Medicines Initiative. Accessed January 22 2021.https://www.imi.europa.eu/projects‐results/project‐factsheets/ardat